News for Healthier Living

ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

October 25, 2026


November 7 2026

November 6 2026

November 5 2026

November 4 2026

November 3 2026

November 2 2026

November 1 2026

October 30 2026

October 29 2026

October 28 2026

October 27 2026

October 26 2026

October 25 2026